Covid-19 Vaccine Latest Update: Clover Biopharma launches human tests
- 4 years ago
Clover Biopharmaceuticals coronavirus vaccine status
Clover Biopharmaceuticals has said the first participants have been dosed with its COVID-19 S-Trimer sub-unit vaccine candidate (SCB-2019) in the Phase 1 first-in-human study.
The development makes it the sixth Chinese developer of a potential Covid-19 vaccine to move into human trials.
Clover’s trial, which is enrolling about 150 adult and elderly patients, will evaluate two different boosters, or adjuvants, from Britain’s GSK and US-based Dynavax in combination with its candidate shot, SCB-2019, Reuters quoted the Chinese company as saying.
The study is being conducted at Linear Clinical Research in Perth, Australia. The trial and Clover’s COVID-19 vaccine program is being supported by the funding and collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI).
Clover said initial safety data from its study was expected in August this year, and it would aim to start broader studies by year end. Its
Clover Biopharmaceuticals has said the first participants have been dosed with its COVID-19 S-Trimer sub-unit vaccine candidate (SCB-2019) in the Phase 1 first-in-human study.
The development makes it the sixth Chinese developer of a potential Covid-19 vaccine to move into human trials.
Clover’s trial, which is enrolling about 150 adult and elderly patients, will evaluate two different boosters, or adjuvants, from Britain’s GSK and US-based Dynavax in combination with its candidate shot, SCB-2019, Reuters quoted the Chinese company as saying.
The study is being conducted at Linear Clinical Research in Perth, Australia. The trial and Clover’s COVID-19 vaccine program is being supported by the funding and collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI).
Clover said initial safety data from its study was expected in August this year, and it would aim to start broader studies by year end. Its